Bacillus Clausii in the Treatment of Acute Community-acquired Diarrhea Among Latin American Children (cadiLAc)

CompletadoFase 4ClinicalTrials.gov

ID: NCT02169817Tipo: INTERVENTIONALInicio: 1 de jul de 2014Fin estimado: 1 de ene de 2016

Traducción no disponible, mostrando original

Resumen

Primary Objective: To demonstrate the effectiveness of treatment with Bacillus clausii probiotic strain (Enterogermina) in combination with oral rehydration therapy (ORT) for a period of 5 days, in the duration of acute community-acquired diarrhea in Latin American children. Secondary Objectives: To evaluate the clinical safety of Enterogermina in acute diarrhea in children and to demonstrate its effectiveness on stool frequency, stool consistency, and number of vomiting episodes. To evaluate parent's overall global assessment. To evaluate the safety and effectiveness of Enterogermina in norovirus acute gastroenteritis (AGE).

Descripción detallada

The maximum duration of study participation for each patient can be 10 days.

Elegibilidad

Edad mínima: 6 MonthsEdad máxima: 5 YearsSexo: ALL

Criterios de inclusión

Infants or children with acute community-acquired diarrhea (≥3 liquid or watery stools occurring in a 24-hour period):
with less than 48 hours duration
aged between 6 months and 5 years of age
whose parents or legal guardians have given their written informed consent
with clinical indication for ORT per formula of World Health Organization

Criterios de exclusión

Infants or children with:
presence of blood, pus, or mucus in stools
severe dehydration
untreatable vomiting
antibiotics indication for the treatment of this acute diarrhea;
hospitalization
expected hospitalization for the next hours due to the poor clinical conditions
treatment with antibiotics, probiotics, or prebiotics within a period of 2 weeks before enrolment (the use of probiotics and prebiotics in dairy food such as yoghurt, cheese, milk prior to the study is permitted)
previous use (within 48 hours) of kaolin, pectin, bismuth subsalicylate, racecadotril, loperamide, atropine and other anticholinergic agents
indication of any other ORT different from the one prescribed in the study
chronic diseases including chronic diarrhea
immunodeficiency (acquired or congenital immunodeficiency)
other infectious comorbid conditions
known hypersensitivity to Bacillus clausii (Enterogermina) or other probiotics
parent/legal guardian who, in the opinion of the Investigator, is unable to complete the patient diary or bring the child for the follow-up visit
participation in another clinical trial in the last 3 months prior to the start of the study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Intervenciones

drug

Bacillus clausii

Pharmaceutical form:aqueous suspension Route of administration: oral

drug

Oral Rehydration Therapy

Pharmaceutical form:vials/sachets for solution Route of administration: oral

Ubicaciones

04

Pilar, Buenos Aires, Argentina

01

Mar del Plata, Argentina

06

San Miguel de Tucumán, Argentina

Patrocinadores

PrincipalSanofi

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Bacillus Clausii in the Treatment of Acute Community-acqu... | EligiMed